Добавил:
shahzodbeknormurodov27@gmail.com Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
Practical Urology ( PDFDrive ).pdf
Скачиваний:
12
Добавлен:
27.08.2022
Размер:
25.91 Mб
Скачать

27

Benign Prostatic Hyperplasia (BPH)

Andrea Tubaro and Cosimo de Nunzio

Historical Background

The first description of the prostate gland goes back to Andreas Vesalius in his book entitled Tabulae anatomicae (1538). In 1564, Ambroise Paré, the Renaissance master of French surgery, described obstructive urinary symptoms. Two centuries later, in 1786, John Hunter, the famous British surgeon, related prostatic enlargement to obstructive symptoms, detrusor hypertrophy, and upper urinary tract dilatation.Transurethral instruments to relieve prostatic obstruction were first developed by Jean Civiale in Paris and Enrico Bottini. Eugene Fuller (1858–1930) and Peter Fryer (1852–1921) in Britain and George Goodfellow (1855–1910) in the United States pioneered surgery of BPH. In the twentieth century, new surgical techniques were developed thanks to people like Terence Millin, Hugh H. Young, James Buchanan Brady, George Luys, Maximilian Stern,Joseph McCarthy,and Frederic Foley.1

Epidemiology and Natural

History

Epidemiology research strictly depends upon the definition of the disease/condition and BPH is not without problem as there is no consensus on a unique definition.2 Current terminology, as revised by Abrams et al. in 2002, describe the objective finding of a Benign Prostatic

Enlargement (BPE), a histological diagnosis (Benign Prostatic Hyperplasia – BPH) and the obstruction that can derive from BPH (Benign Prostatic Obstruction – BPO).3 Unless the patient suffers complications of BPH such as renal failure, bladder stones or diverticula, recurrent urinary tract infection, and acute or chronic retention and surgery is performed on the enlarged prostate gland, treatment is targeted at reducing lower urinary tract symptoms (LUTS) that can be associated with but are not uniquely due to BPH. This is the reason why, in the lack of a univocal definition of BPE/BPH/BPO, most epidemiological work on BPH is based upon the incidence and prevalence of LUTS with the risk of including patients whose symptoms depend on causes other than BPH. Analysis of the General Practice Research database from the UK suggests that both incidence and prevalence of LUTS increase with age. Incidence values of 5 and 50 per 1,000 person-years were observed in men aged 45–49 and > 80 years, respectively. Prevalence increased from 3.5% in the fourth decade to 30% in men of 85 years or older.4 The increase of LUTS prevalence with age has been confirmed in several studies performed in different countries/populations although slight differences in the absolute age-specific prevalence value were observed.

Although BPH is an androgen-dependent condition (it does not develop in castrated men and families with a 5-alpha reductase deficiency), there is little evidence of an effect of hormone levels on clinical manifestations of the

C.R. Chapple and W.D. Steers (eds.), Practical Urology: Essential Principles and Practice,

361

DOI: 10.1007/978-1-84882-034-0_27, © Springer-Verlag London Limited 2011

 

 

 

 

 

 

362

 

 

 

 

 

 

 

Practical Urology: EssEntial PrinciPlEs and PracticE

disease in population studies. Some degree of

MTOPS.9 Using a stricter parameter such as

association has been found between BPH and

increase of prostate volume of 26% or higher,

growth factors such as Insulin Growth Factor-1

22.6% of men progressed over a 4.2-year period

and its binding globulin (IGFBP-3). LUTS have

in the population-based Krimpen study.8 PSA

also been correlated with sexual dysfunction

concentration is known to be related to age and

and the relation holds true in different studies

prostate volume; in the Krimpen study, a 5%

also after data were adjusted for age although no

increase of serum PSA per year was seen. A

clear explanation has been found. A weak asso-

shorter PSA doubling time was observed in men

ciation between clinical manifestations of BPH

with BPH compared to those without it. Asian

and cardiovascular disease has been described.

populations were recently investigated to obtain

No relation between LUTS and lifestyle factors

epidemiological data on LUTS/BPH. Prevalence

(namely diet and exercise) has been observed.

of LUTS is comparable to that observed in

Since surgical treatment of BPH was devel-

Europe and USA with an 8% increase per decade

oped, the condition is no longer life-threatening

(from 41.7% in the fifth decade to 65.4% in men

but remains progressive. Studies on the natural

of 70 years or older). Although mean prostate

history of the disease tell us that an increase of

volume in Japan community-based studies is

about 0.2 points/year in the IPSS scale is

lower than in Caucasian-American and Africa-

expected; 50–80% of men will remain stable

American series, Japanese prostates are more

over a 1–5-year period with a 20–50% progres-

glandular. In Malaysia no difference in Qmax and

sion rate also depending on the definition of

prostate volume was found among Chinese,

progression and type of population. The risk of

Malay, and Indian populations.10

acute urinary retention (AUR) varies from 2 to

 

 

 

18 per 1,000 person-years with lower values

 

 

 

observed in community studies (2–6.8%) and

Pathophysiology

 

higher ones in the placebo arms of clinical trials.

 

Age, symptom severity, and maximum flow rate

 

 

 

(Qmax) were independent predictors of AUR. In

The term “prostatism,” suggesting a cohort of

the Olmstead County study, an age-related dete-

symptoms deriving from the enlarging prostate,

rioration of flow rate was observed with a 1.3%

has been replaced by the term “Lower Urinary

decrease per year in men in the 40s and 6.5%

Tract Symptoms.”11 LUTS terminology was rede-

decrease in men in their 70s.5 Longitudinal stud-

fined 8 years later and now includes filling/

ies of voiding dynamics are rare. Thomas et al.

storage,

emptying/voiding,

and postvoiding

reported no significant increase of bladder out-

symptoms (Table 27.1).3 Voiding symptoms are

flow obstruction over a 13.9-year period

known to be more prevalent than storage ones

although decrease of detrusor contractility was

althoughthesearemorebothersome.12 Frequency

found.6 The prostate gland tends to grow over

with reduced voided volume may be associated

time; population studies suggested a 1.6–2.0%

with detrusor overactivity, significant post-void

increase of prostate volume per year.7,8 A 4.5%

residual, bladder neoplasms, fear of urinary

increase was observed in the placebo arm of the

retention,

and psychogenic

causes. A small

Table 27.1. lUts

 

 

 

 

Filling/storage

Emptying/voiding

Postvoiding symptoms

Frequency

Hesitancy

 

Post-micturition dribbling

Urgency

straining to void

Feeling of incomplete emptying

nocturia

Poor stream

 

 

 

Urgency incontinence

intermittency

 

 

 

stress incontinence

dysuria

 

 

 

nocturnal incontinence

terminal dribbling

 

 

Bladder/urethral pain

 

 

 

 

absent or impaired sensation

 

 

 

 

363

BEnign Prostatic HyPErPlasia (BPH)

bladder capacity may occur because of fibrosis,

examination; urinalysis; biochemical testing;

noninfectious inflammatory disorders, irradia-

post-void residual urine measurement, imaging,

tion, and previous bladder surgery. Frequency

and endoscopy of lower urinary tract (LUT)

with normal voided volume may depend upon

(Table 27.2, Figs. 27.1 and 27.2).13

polydipsia, osmotic diuresis, or diabetes insipi-

History and physical examination aims at

dus. Urgency (the sudden compelling desire to

diagnosing concomitant conditions of the blad-

void, which is difficult to defer), urgency inconti-

der, the central nervous system, or other organs

nence, and overactive bladder indicate neuro-

that may be responsible for LUTS beyond benign

genic origin (reduced suprapontine inhibition,

and malignant disorders of the prostate.

damaged axonal paths in the spinal cord,

Frequency–volume charts are instrumental to

increased afferent input to the lower urinary

analyze dayand night-time frequency, mean

tract, loss of peripheral inhibition, enhancement

voided volume, total urine output, nocturnal

of excitatory neurotransmission, in the micturi-

urine output, urgency and urgency incontinence

tion reflex pathway), myogenic (due to the effect

episodes. Threeto seven-day charts are used

of BOO on smooth muscle fibers) and structural

with voided volumes recorded at least for 1 day.

causes. Nocturia, defined as the need to wake up

The instrument is accurate and inexpensive and

at night to void, is a troublesome symptom that

its widespread use should be encouraged.

should always be distinguished from nocturnal

Symptom score have been developed to stan-

polyuria. Prevalence of nocturia increases with

dardize the assessment of symptom severity by

age and is sometimes considered part of the nor-

using questions that have been psychometrically

mal aging process.Voiding symptoms include all

validated although they can also be used to pre-

symptoms experienced during voiding. There is

dict the response to treatment and to assess

no pathophysiological correlation between these

treatment outcome. Different symptom scores

symptoms and urodynamic parameters of outlet

are available and have been validated in several

obstruction and this is why the term“obstructive

languages (IPSS, ICIQMLUTS, Dan PSS, OABq);

symptoms” has been dropped. The relation

they all contain one or more questions about

between LUTS and BPH is complex particularly

quality of life and symptom bother. Although

when epidemiological data suggested a similar

the IPSS is the most popular symptom score, it

prevalence in women.12

does not address urinary incontinence and may

 

therefore be suboptimal whenever continence is

 

impaired. Urinalysis is a recommended test also

Patient Assessment

at the primary level because it allows to diag-

nose concomitant conditions that may or may

 

 

not be associated with LUTS such as hematuria,

Patient assessment aims at establishing the

but it is also instrumental in suspecting urinary

tract infection, a common cause of LUTS.

pathophysiology of LUTS in the individual sub-

Although there is no association between BPE,

ject and include: history taking, frequency–

BPH/BPO, and chronic kidney disease, some

volume charts, and symptom scores; physical

national guidelines still recommend to measure

Table 27.2. diagnostic tests

 

 

Basic evaluation

Specialized management

 

Recommended tests

Recommended tests

Optional tests

History

detailed quantification of symptoms

transrectal ultrasonography

 

by validated questionnaires

of the prostate

assessment of symptoms and bother

Uroflowmetry

Ultrasound imaging of the upper

 

 

urinary tract or intravenous

 

 

urography

Urinalysis

Post-void residual urine

Endoscopy of the lower urinary

 

 

tract

serum prostate-specific antigen (when

Pressure-flow studies

 

indicated)

 

 

Frequency–volume chart (voiding diary)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

364

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Practical Urology: EssEntial PrinciPlEs and PracticE

 

 

 

 

 

 

Basic management of LUTS in men

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Recommended Tests:

 

 

Complicated

 

 

 

 

 

LUTS

 

 

-

Relevant medical history

 

 

 

 

 

 

 

 

 

 

 

 

LUTS:

 

 

 

 

 

 

 

- Assessment of LUTS

 

 

 

 

 

 

 

 

cause little or

 

 

 

- Suspicious DRE

 

 

 

 

 

 

 

 

symptom severity and

 

 

 

 

 

 

 

no bother

 

 

 

 

 

 

 

 

 

 

 

 

bother

 

 

- Hematuria

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

-

Physical examination

 

- Abnormal PSA

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

including DRE

 

- Pain

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Reassurance

 

 

-

Urinalysis

 

- Infection3

 

 

 

 

 

 

 

- Serum PSA1

 

- Palpable bladder

 

 

 

 

 

and follow-up

 

 

-

Frequency - volume chart2

 

- Neurological

 

 

 

 

 

Predominant

 

 

 

 

 

 

 

 

 

 

 

 

 

disease

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

significant nocturia

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Bothersome LUTS

 

 

 

 

 

 

 

 

 

Frequency-volume chart

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Polyuria

 

 

 

 

 

No Polyuria

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1

 

Polyuria

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

24-hour output 3 liters

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Standard Treatment

 

 

 

 

 

 

 

Lifestyle and fluid intake

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

- Alter modifiable factors

 

 

 

 

 

 

 

is to be reduced4

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Drugs

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fluide and food intake

 

 

 

 

 

 

 

Nocturnal polyuria

 

 

 

 

 

 

 

 

2

 

 

 

 

 

 

- Lifestyle advice

 

 

 

 

33% output at night

 

 

 

 

 

 

 

 

 

 

 

 

Fluid intake to be

 

 

 

 

 

- Bladder training

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

reduced Consider

 

 

 

 

 

Drug treatment5

 

 

 

 

 

 

 

desmopressin

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1When life expectancy is > 10 years and if the diagnosis of prostate

 

cancer can modify the management.

Failure

Success in

2

When significant nocturia is a

 

 

relieving

 

 

 

 

bothersome

 

predominant symptom.

 

 

 

 

 

LUTS:

 

 

 

 

 

3

Assess and start treatment before

 

 

 

 

 

 

 

 

 

 

 

referral.

 

 

 

 

 

 

 

 

Continue

4

In practice, advise patients with

 

 

 

symptoms to aim for a urine output

 

 

treatment

 

 

 

 

 

 

 

 

 

 

of about 1 liter/24 hours

 

 

 

 

 

 

 

 

Specialized management

5

See pages 10-12.

 

 

 

 

 

 

 

Figure 27.1. algorithm for basic management of male patients with lUts (From Mcconnell et al.13 with permission).

serum creatinine. Prostate-specific antigen (PSA) is recommended by most guidelines in patients with a life expectancy of 10 years or greater; the test can be used as a screening tool for prostate cancer, is a proxy for prostate volume, and is a good prognostic parameter for BPH progression. Measurement of post-void residual has been recommended as part of the initial evaluation although there is a weak

evidence for it. The relation between elevated PVR and UTI is in fact evident in the pediatric and neurogenic populations but scanty in the BPH patient. PVR values below 50–100 mL are considered to be normal and value >300 mL is used to identify patients at risk of unfavorable outcome. Imaging of the LUT includes bladder and prostate. Bladder imaging is usually performed for evaluating PVR but also provides

365

BEnign Prostatic HyPErPlasia (BPH)

Specialized management for persistent bothersome LUTS after basic management

 

 

 

 

 

 

 

 

 

 

 

Recommended tests:

 

 

 

 

 

OAB

 

 

 

 

- Validated questionnaires

 

 

 

 

(Storage symptoms)

 

 

- FVC (frequency-volume chart)

 

 

 

 

No evidence of BOO

 

- Flowrate recording

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

- Residual urine

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

- Lifestyle

 

 

 

 

 

 

 

 

Evidence of BOO

 

 

 

 

MIST

 

 

 

 

 

 

 

 

Discuss Rx options

 

 

 

 

 

intervention

 

 

 

 

 

 

 

 

 

 

 

or

 

- Behavioral

 

 

 

 

 

 

 

 

shared decision

 

 

Surgery option

 

therapy

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

- Antimuscarinics

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Medical therapy

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

option

 

 

 

 

 

 

 

 

 

 

Mixed

OAB

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Failure

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Predominant BOO

 

 

 

 

 

 

 

 

 

 

 

 

and

BOO

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Reassess and

 

Antimuscarinics

 

Small gland/

 

Larger

 

gland

 

 

 

 

 

 

and/or low PSA1

 

and/or higher PSA2

 

consider invasive

 

and

 

 

 

 

 

 

 

 

 

 

 

 

 

 

therapy of OAB

 

α-blockers

 

 

α-blockers

 

α-blockers +

 

 

 

 

 

 

 

5α-reductase inhibitors

 

 

(botulinum toxin

 

 

 

 

 

 

 

 

 

 

 

 

 

 

and

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

neuromodulation)

 

 

 

 

 

 

 

 

Failure

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OAB: Overactive Bladder

BOO: Bladder Outlet

Obstruction

MIST: Minimally Invasive

Surgical Treatment

1PSA < 1.5 ng

2PSA > 1.5 ng

Offer MIST or Surgery to patient

Evaluation clearly suggestive of

 

 

 

 

 

 

YES

 

obstruction ? (Qmax < 10ml/s)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NO

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Pressure-Flow Studies

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NO

 

 

Obstruction ?

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

YES

 

 

 

 

Treat appropriately. If inter-

 

 

 

 

ventional therapy is pursued,

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

patients need to be informed

 

 

 

 

 

 

 

 

 

 

 

 

Proceed with

 

of possibly higher failure rates

 

 

 

 

selected technique

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Figure 27.2. algorithm for specialized management of male patients with persistent lUts following basic management (From Mcconnell et al.13 with permission).

information regarding possible comorbidities (bladder stones, diverticula, neoplasms, etc.), intravesical prostate protrusion, prostate volume, and bladder wall thickness. Transrectal imaging of the prostate cannot be used to diagnose or rule out prostate cancer in patients with LUTS but allows accurate evaluation of prostate

volume and gland morphology. Endoscopy is an optional test in all guidelines, because it cannot diagnose BPO although it may rule out concomitant disorders of the urinary bladder and urethra that may be responsible for LUTS. Urodynamics include different tests although uroflowmetry and pressure-flow study are most